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Jerry Tran,1 Emily E. Norder,1 Philip T. Diaz,1 Gary S. Phillips,2 Pat Elder,3
Steven M. Devine,3 Karen L. Wood1Bronchiolitis obliterans syndrome (BOS) is a progressive, insidious lung disease affecting allogeneic hemato-
poietic stem cell transplantation recipients. Unfortunately, there is no standardized approach for treatment
of BOS in post–hematopoietic stem cell transplantation patients. Pulmonary rehabilitation is a standard
treatment in emphysema, an irreversible obstructive lung disease secondary to tobacco abuse. The National
Emphysema Treatment Trial (NETT) demonstrated improved exercise tolerance, decrease dyspnea, and in-
crease of quality of life in patients with severe emphysema after pulmonary rehabilitation. We hypothesized
that pulmonary rehabilitation may benefit patients with BOS. Patients with BOS were identified retrospec-
tively from January 2005 to the present. Patients who enrolled in pulmonary rehabilitation were included in
the study. We obtained summaries via chart review of each patient’s progress after pulmonary rehabilitation
enrollment from his or her respective rehabilitation centers. Six-minute walk distances, spirometry, and
pulmonary symptoms were compared before and after the completion of pulmonary rehabilitation.We iden-
tified 11 patients with BOS documented from their pulmonologist’s clinical notes who were enrolled into
pulmonary rehabilitation. Ten of the 11 patients completed pulmonary rehabilitation. All patients had im-
provement in their 6-minute walk distances after the completion of pulmonary rehabilitation, with an average
improvement in distance of 307 feet (P value5 .005). Six of the 10 patients completed Short Form-36 (SF-36)
questionnaires before and after rehabilitation. There was a significant improvement in the physical function-
ing score (P value 5 0.029). Pulmonary rehabilitation seems to improve 6-minute walk distance, subjective
symptoms of dyspnea, and exercise tolerance in patients with BOS. This may be an important adjunctive ther-
apy for a debilitating disease with limited treatment options.
Biol Blood Marrow Transplant 18: 1250-1254 (2012)  2012 American Society for Blood and Marrow TransplantationKEY WORDS: Bronchiolitis obliterans syndrome, BOS, Hematopoietic stem cell transplantation, Pulmonary
rehabilitationINTRODUCTION
Bronchiolitis obliterans syndrome (BOS) is themost
common and serious form of chronic pulmonary graft-
versus-host disease (GVHD). The prevalence varies
depending on the definition used, but was recently esti-
mated at 5.5% using a modified National Institutes of1The Ohio State University Medical Center, Department
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6/j.bbmt.2012.01.017Health (NIH) definition [1]. The disease negatively
and substantially contributes tomorbidity andmortality
[2]. Patients typically develop symptoms within
18 months of transplantation and report symptoms of
dyspnea, cough, and wheezing [2,3]. Diagnosis can be
established clinically based on symptoms, new fixed
airflow obstruction, and air trapping on imaging in a
patient usually with other evidence of chronic GVHD
[3,4]. Unfortunately, the disease remains difficult to
manage and mortality remains high even with
attempts of increasing immunosuppression. Other
pharmacologic and non-pharmacologic therapies need
to be investigated in this patient population including
pulmonary rehabilitation.
Pulmonary rehabilitation is a standard treatment in
emphysema, an irreversible obstructive lung disease sec-
ondary to tobacco abuse. The National Emphysema
Treatment Trial (NETT) and prior randomized con-
trolled trials demonstrated improvement in exercise
Biol Blood Marrow Transplant 18:1250-1254, 2012 1251Pulmonary Rehabilitation and Bronchiolitis Obliterans Syndrometolerance and quality of life along with decreased
dyspnea in patients with chronic obstructive pulmonary
disease (COPD) [5-8]. Recent COPD guidelines
recommend pulmonary rehabilitation in all symp-
tomatic patients with COPD and forced expiratory
volume in 1 second (FEV1)\50% [9]. The NIH con-
sensus statement on chronic GVHD recommends pul-
monary rehabilitation in patients with BOS based on
expert opinion, but there are no studies looking at this
treatment [10]. Evaluating the effect of a standardized
exercise programon patients identified to have presence
ofBOScould potentiallyoffer a treatment that improves
exercise tolerance and quality of life in a disease with few
options.MATERIALS AND METHODS
Patient Identification
Patients who were being seen at the outpatient pul-
monary clinic were identified retrospectively from
January 2005 to the present if they had BOS after allo-
geneic stem cell transplantation (SCT) and had been
enrolled in pulmonary rehabilitation. All patients diag-
nosed with BOS fit the NIH criteria, which included
an FEV1/forced vital capacity (FVC) ratio \70%
and an FEV1\75% and either evidence of air trapping
by computed tomography or elevated residual volume
(.120%) [11]. Data were collected from an institu-
tional database and from retrospective medical chart
review. The study was approved by The Ohio State
University Institutional Review Board.Pulmonary Rehabilitation
The majority of patients completed their rehabili-
tation at our institution, but 4 patients completed the
program at an outside institution due to the proximity
to their homes. All patients participating in our pro-
gram completed 24 sessions of rehabilitation over an
8-week duration. Exercise classes covered nutrition,
medication and oxygen safety, pursed lip breathing
and other breathing techniques, and use and care of
a metered dose inhaler. Exercise included upper and
lower body strength training using a combination of
free weights and weight machines. Cardiovascular ex-
ercise included the recumbent bike, treadmill or step
machine, and the upper body bike. Individuals usually
started the program using the treadmill for 10minutes,
the bike for 8 minutes, and the upper body bike for
6 minutes. The initial exercise prescription was guided
by cardiopulmonary exercise testing or the 6-minute
walk testing and then speed, incline, or resistance
were gradually increased as tolerated individually
with a goal of 45 minutes of cardiovascular exercise
per session. Strength training was usually about 20
minutes per session but varied from person to person.Of the 11 patients enrolled in the study, 4 performed
their rehabilitation at 3 outside institutions. Outside
programs were reviewed and were not found to be sig-
nificantly different in content than our institution’s
program. The duration of outside programs ranged
from 8 to 12 weeks, and the 4 patients completed
from 21 to 36 sessions.
Data Collection
We reviewed spirometry/pulmonary function tests
(PFTs), 6-minute walk tests, and medical records from
the InformationWarehouse at the Ohio State Univer-
sity (our computerized record storehouse). The walk
tests and Short Form-36 (SF-36) scores were assessed
during the patient’s rehabilitation entrance and exit
visits. The timing of spirometry varied, however, the
most recent spirometry before rehabilitation and after
the treatment portion of rehabilitation was used for
comparison. Symptoms of dyspnea, cough, wheezing,
and fatigue were retrospectively evaluated by docu-
mentation of subjective symptoms at each patient’s
most recent pulmonary clinic visit before pulmonary
rehabilitation and the next visit after the completion
of the treatment portion of pulmonary rehabilitation.
Statistical Analysis
Pre- and post-rehabilitation 6-minute walk dis-
tances and SF-36 subscores were compared using
a paired t test. A P value of\ .05 was considered signif-
icant. All analyses were run using Stata 10.2 or 11.1
(Stata Corporation, College Station, TX).RESULTS
Eleven patients were included in the study; how-
ever, only 10 patients completed the rehabilitation
program. One patient did not complete the program
due to chronic pain issues. Patient demographics are
noted in Table 1. The average age was 48 years old
and a majority of the patients were men. Three of
the patients had a significant smoking history, and 2
of the 3 had a documented history of COPD. Only 1
patient had a severely depressed ejection fraction on
echocardiogram.
The most common reason for transplantation in
the population studied was acute myelocytic leukemia
(36%). Transplantation characteristics and GVHD
data are shown in Table 1. The most common condi-
tioning regimen was fludarabine/busulfan with or
without anti-thymocyte globulin (54.5%). Ten of the
11 transplantations were peripheral blood SCTs and
6 were sibling matched donors, whereas 5 were unre-
lated. HLA typing was done by high-resolution
DNA typing for HLA-A, B, C, DRB1, and DQB1.
Three of the 11 patients had a 9 of 10 HLA match,
and the rest were 10 of 10.
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1252 Biol Blood Marrow Transplant 18:1250-1254, 2012J. Tran et al.Eight of the 11 patients had evidence of acute
GVHD; the information on patient number 1 was un-
available. Ten of the 11 patients had severe chronic
GVHD, as assessed by the NIH Consensus criteria
[11]. The other patient did not have any organ involve-
ment besides pulmonary disease. There was a wide
range of days to diagnosis of BOS after transplanta-
tion. All patients with pre-transplantation PFTs
demonstrated a drop of at least 10% in FEV1 after
transplantation, andmost had a drop of.25%. Patient
number 1 did not have pre-transplantation PFT be-
cause she underwent transplantation at age 7.
PFTvalues and6-minutewalk distances for each pa-
tient before and after rehabilitation are shown in
Figure 1. Summary data can be seen in Table 2. There
wasnosignificant change in spirometrywhencomparing
pre- and post-rehabilitation (P 5 .446 for FEV1, and
P5 .822 for FVC, Table 2). All patients who completed
pulmonary rehabilitation improved their 6-minute walk
distance (P5 .005). Six-minute walk distance increased
an average of 307 feet post-rehabilitation. SF-36 surveys
wereperformedbefore and after rehabilitation in5of the
10 patients (Table 2). There was a significant improve-
ment in the physical functioning score by a mean of
14.4 points (P value5 0.029).DISCUSSION
This study demonstrates a marked improvement in
objective exercise tolerance, subjective symptoms, and
quality of life. There was improvement in 6-minute
walk distance after pulmonary rehabilitation. Patients
improved their 6-minute walk distance by an average
of 307 feet,which iswell above the 76-foot improvement
seen in the NETT [5]. The majority of patients experi-
enced less dyspnea based on clinic notes, and one-half of
thepatientshad subjective improvement in their exercise
tolerance post-rehabilitation. The SF-36 physical func-
tioning score improved in the patients who completed
the form before and after rehabilitation, although there
were not significant changes in the other SF-36 do-
mains. There was little change on spirometry after
rehabilitation, which is consistent with the findings in
the previous rehabilitation trials in COPD [5,6].
The rationale behind the positive effects seen in our
patients can be extrapolated from other patients with
chronic lung diseases. Pulmonary rehabilitation has
been evaluated predominantly in patients with COPD.
Pulmonary rehabilitation typically involves weeks of
supervised exercise, strength training, education, nutri-
tional assessment, and psychosocial evaluation [12].
Studies have demonstrated that pulmonary rehabilita-
tion increases exercise capacity, improves quality of
life, and decreases dyspnea in patients with COPD
[5-8]. It is thought that the exercise limitation seen in
COPD is due to multiple factors including hypoxemia,
01
2
3
4
5
FE
V
1
Pre-transplant Pre-Rehab Post-Rehab
0
2
4
6
FV
C
Pre-transplant Pre-Rehab Post-Rehab
.2
.4
.6
.8
1
FE
V 1
/F
VC
Pre-transplant Pre-Rehab Post-Rehab
500
1,000
1,500
2,000
6 
m
in
ut
e 
wa
lk,
 fe
et
Pre-transplant Pre-Rehab Post-Rehab
Figure 1. (A) Forced expiratory volume in 1 second (FEV1; liters) for each subject pre-transplantation, pre-rehabilitation, and post-rehabilitation. (B)
Forced vital capacity (FVC; liters) for each patient pre-transplantation, pre-rehabilitation, and post-rehabilitation. (C), FEV1/FVC ratio (percentage) for
each patient pre-transplantation, pre-rehabilitation, and post-rehabilitation. (D) Six-minute walk distance (feet) pre-rehabilitation and post-rehabilitation.
Biol Blood Marrow Transplant 18:1250-1254, 2012 1253Pulmonary Rehabilitation and Bronchiolitis Obliterans Syndromehyperinflation, cardiac dysfunction, and potentially
respiratory muscle weakness [8,12]. Skeletal muscle
weakness also plays a role in exercise intolerance and
has been attributed to underlying inflammation,
frequent use of corticosteroids, and deconditioning,
among other factors [8,12]. By addressing these factors
along with the other systemic manifestations of
COPD, pulmonary rehabilitation has improved
important endpoints in patients with COPD. A recent
guideline update from the American College of
Physicians, American College of Chest Physicians,
American Thoracic Society, and European RespiratoryTable 2. Summary Outcomes for SF-36 Domains, 6-Minute
Walk Distance, FEV1, and FVC
Clinical Outcome
Mean (SD)
P value*
Pre-
rehabilitation
Post-
rehabilitation
FEV1 1.48 (0.65) 1.37 (0.79) .446
FVC 2.51 (1.02) 2.54 (0.91) .822
Six-minute walk, feet 1291 (373) 1598 (333) .005
SF-36 Domains
Physical functioning 43.9 (15.3) 56.7 (16.8) .029
Role functioning–physical 18.2 (21.0) 20.9 (24.7) .180
Role functioning–emotional 77.4 (25.7) 77.9 (20.7) .961
Bodily pain 63.2 (18.5) 58.4 (22.3) .713
General health 42.4 (9.0) 41.2 (12.8) .742
Vitality 37.3 (20.3) 53.5 (7.4) .071
Social functioning 57.3 (16.0) 59.8 (12.1) .688
Mental health 74.2 (17.1) 75.1 (13.1) .784
Reported health transition 2.3 (1.4) 2.5 (1.05) .771
SF-36 indicates short form-36 questionnaire; FEV1, forced expiratory
volume in 1 second; FVC, forced vital capacity.
*P value based on a paired t test.Society recommends pulmonary rehabilitation in
patients with an FEV1 \50% but can also be
considered for patients above that threshold [9].
Like COPD, BOS is a chronic pulmonary condi-
tion characterized by irreversible air flow obstruction
and is associated with hyperinflation [2,3]. Also
similar to patients with COPD, it has been shown
that patients undergoing SCT, in general, suffer from
skeletal and respiratory muscle weakness. White et al.
[13] noted that maximal inspiratory muscle strength,
maximal expiratory muscle strength, and grip strength
were decreased in a significant number of patients even
before undergoing transplantation. These patients also
were noted to have decreased exercise tolerance before
transplantation as evidenced by a decreased 6-minute
walking distance [13]. While the etiology for this is
not specifically known, it has been attributed to the
patient’s underlying disease and/or treatment [13,14].
At the same institution, it was demonstrated that
respiratory and skeletal muscle weakness continues to
be a significant issue after transplantation [14].
Given these findings, exercise therapy has been
evaluated in SCT patients around the time of trans-
plantation with evidence of benefit. Studies have dem-
onstrated improved quality of life [15,16], muscle
strength [15], physical fitness [15-18], and fatigue
measures [16,18,19] with exercise around the time of
transplantation. There is also 1 small retrospective
study of patients that showed an association between
the number of steps a patient could take with the
duration of hospitalization [20]. However, to our
knowledge, there are no data evaluating pulmonary
1254 Biol Blood Marrow Transplant 18:1250-1254, 2012J. Tran et al.rehabilitation in patients who develop BOS posttrans-
plantation until now.
There are limitations of our study to note. First, it
is a small retrospective study and comparison to a con-
trol population was not feasible. There are also limita-
tions as the clinic visits were not at standardized times
and the time from rehabilitation to the pre- and post-
visits varied. Ideally, patients would be seen at a specific
interval before and after rehabilitation for measure-
ment of physiologic measures and symptoms. Another
issuewas that we did not have 1 center providing the re-
habilitation, which limited some of the analysis. All of
the centers were accredited, reputable, and used the ba-
sic multidisciplinary approach; however, homogeneity
would have provided easier comparison of the testing
pre- and post-rehabilitation. This also limited our abil-
ity to analyze quality-of-life surveys because different
centers had differing preferences for which survey
they used. The data used to compare quality of life
was obtained using the SF-36 survey, which has not
been validated in this specific patient population, so it
may not be an accurate reflection of quality-of-life
domains. Larger controlled studies would ideally be
performed to confirm our findings, but this may be dif-
ficult given the low prevalence of this disease.
Despite these limitations, the improvement in
aspects of quality of life and walk distance in all 10 pa-
tients are important outcomes in this patient popula-
tion. With few treatment options available for
patients with bronchiolitis obliterans, our study dem-
onstrates improvement in symptoms and exercise
capacity from a historically low-risk treatment. Pul-
monary rehabilitation should be strongly considered
as an adjunct treatment for patients who develop
bronchiolitis obliterans, which is compatible with
NIH Consensus recommendations for supportive
care of chronic GVHD [10].ACKNOWLEDGMENTS
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